

REQUEST FOR APPLICATIONS

Joint Call for Research Projects on HIV, HBV, and HDV CURES

October 26th 2026

APPLICATION DEADLINE: 11:59pm CET (10:59pm UTC) January 12th, 2027

Proposals will not be accepted after this date and time

1. Introduction


The ANRS Emerging Infectious Diseases (ANRS MIE) and the German Center for Infection Research (DZIF) have identified the acceleration of HIV and Hepatitis cure as a common strategic priority.

By jointly funding this call, the ANRS MIE and the DZIF aim to promote and accelerate research focused on strengthening translational and pre-clinical research in the field of HIV and hepatitis cure.

This call also aims to encourage and support cross-country collaborations between France and Germany, fostering cooperation and alignment in scientific research between institutions, research teams, and stakeholders in both countries. By providing a structured framework for collaboration, ANRS MIE and DZIF intend to facilitate the development of strong and sustainable scientific partnerships and to strengthen long-term scientific collaboration between researchers in Germany and France.

Overall, this initiative seeks to accelerate the translation of scientific discoveries, observations, and concepts developed in the laboratory into practical therapeutic strategies for patients, with the ultimate goal of contributing to the elimination of HIV and hepatitis.

2. Call Timeline and key dates



Key Dates	Event
October 26th	Opening of the Call for Proposals
January 12th	Application submission deadline
May	Notification of results
September - 2027	Anticipated project start date

3. Scientific scope

The joint call aims to support innovative translational and pre-clinical research on HIV and hepatitis (HBV and HDV) cure. The objective is to accelerate the development of strategies leading to functional cure and/or viral eradication.

Applications must demonstrate:

- A clear focus on HIV and/or hepatitis (HBV and/or HDV) cure;
- A strong scientific rationale explaining how the proposed strategy could contribute to functional cure or viral eradication;
- A clear translational pathway describing how the proposed research could ultimately progress towards clinical application;
- An innovative research approach with the potential to advance the field of HIV and/or hepatitis cure.

Encouraged scientific approaches

Projects may include, but are not limited to:

- Development of novel therapeutic strategies, including immunomodulatory approaches targeting viral reservoirs;
- Development, validation, or application of relevant preclinical models to investigate viral persistence, viral reservoirs, and mechanisms of immune control;

- Use of clinical samples and datasets to identify mechanisms of viral control or novel therapeutic targets supporting cure strategies;
- Ambitious, high-risk/high-gain approaches with the potential to generate transformative scientific advances.

Added value

The following aspects will be considered as strengths during evaluation, where relevant:

- Leadership by early-career or new investigators;
- Partnerships with pharmaceutical or biotechnology companies.

Scientific exclusion criteria

The following types of proposals are not eligible:

- Projects that do not explicitly address HIV and/or HBV/HDV cure;
- Projects focusing exclusively on the basic mechanisms of viral persistence without a clearly defined translational perspective;
- Projects dedicated solely to the development of assays or biomarker identification for evaluating cure strategies;
- Projects conducted exclusively in established cell lines without relevant preclinical or translational components.

4. Eligibility

This section brings together all the criteria an application must satisfy to be considered eligible: consortium composition, administrative requirements, scientific scope exclusions, and general exclusion conditions.

4.1 Consortium Composition

Recognizing the cure of HIV and hepatitis as a common strategic priority, the ANRS MIE and DZIF are launching this joint call to promote collaboration between researchers based in Germany and France and accelerate progress towards this goal.

As thus, projects submitted under this call must be collaborative, involving at least one French and one German research team acting as the two co-leading teams of the project. Additional research teams (up to 2 per country) may be included as partners to provide

complementary expertise, access to specific resources or technologies, or to support multidisciplinary approaches. Such participation should be scientifically justified and remain proportionate to the project's objectives

The partnership must demonstrate balanced and effective Franco-German collaboration (see Sections 5 and 6.3).

Each Principal Investigator may act as the lead applicant on only one proposal submitted to this call. There is no limit to the number of proposals in which a researcher may participate as a project partner.

4.2 Administrative Eligibility criteria

Applications must be submitted in English, before the submission deadline, and include all required documents and information.

Eligible applicants

This joint call supports collaborative projects involving research teams from France and Germany.

The two co-leading Principal Investigators (PIs) must be:

- French Public research institutions: the beneficiaries of the funding are French higher education and/or research institutions or groups of such institutions, as well as French private institutions contributing to the public service missions of higher education and research, in accordance with Article L. 732-1 of the Education Code.
- German Public research institutions: a Principal Investigator affiliated with a DZIF member institution or an associated partner institution or associated partners (See appendix “DZIF_member_institutions_and_ass_partners”).

Additional academic partners fulfilling the above conditions may be included where scientifically justified, in accordance with the collaborative framework described in Section 4.1.

Funding for successful projects will be provided independently by ANRS MIE and DZIF. Consequently, beneficiaries will enter into separate funding agreements with their respective funding organisation, each subject to its own rules and requirements. Applicant teams are strongly encouraged to consult the call secretariat of ANRS MIE or DZIF to confirm that they fulfil the respective funding criteria.

4.3 Participation of private companies

Private, for-profit companies are not eligible to receive funding through this call.

However, they may participate in the consortium as non-funded project partners.

4.4 Exclusion conditions

- To avoid conflicts of interest, staff directly involved in the call implementation are not eligible to apply to this call and must maintain strict confidentiality (Firewall measures) regarding any sensitive/confidential information related to the call.
- Simultaneous submission of the same proposal to another ANRS MIE or DZIF call is permitted. However, if a proposal is awarded funding through the first call, it will be withdrawn from the evaluation process of the second call.
- Proposals involving more than four additional partners in total, excluding the two co-leading teams) are not eligible.
- Proposals involving more than three partner teams per country, in addition to the co-leading team, are not eligible. For example, a proposal including one French co-leading team and three French partner teams would be declared ineligible, even if the German side complies with this limit (see section 4.1).

Applications that do not comply with these administrative eligibility requirements will be declared ineligible and will not be forwarded to the peer-review process.

5. Available Funding & Duration

The total budget allocated to this joint call is €2 million.

Up to four projects will be funded:

- Two projects focused on HIV
- Two projects focused on hepatitis

The total requested budget per project must fall within the range of €300,000 to €500,000. Funding is provided by two funders: ANRS for the French partners, including the French coordinator team and DZIF for the German partners, including the German coordinator team. The amount requested from each funder should not exceed €250,000. Funding should be balanced between the French and German partners, with a maximum difference of 60/40% between the amounts requested from ANRS and DZIF. External co-financing is allowed, however provided the project remains fully feasible with ANRS/DZIF funding alone; external co-financing must not be essential to the project's implementation.

Duration

Project duration must be 24, or 36 months, with 36 months as the maximum.

6. Application and Review Process

6.1 Instructions for Application

Applications must be submitted in English on the ANRS MIE [Apogée](#) platform, also available from [ANRS MIE website](#), between October 26th, 2026 and January 12th, 2027, and must include all the elements required for the scientific and technical evaluation of the project. Prior registration on the Apogée submission platform is required to submit an application. Detailed guidance on how to use the Apogée platform is provided in the "Application Guide-Apogée platform" appendix.

The complete submission file consists of the following elements:

- **Administrative section:** administrative and scientific information on the project partners, including the list of the most significant scientific publications of the last five years, publications related to the Call thematic areas, and patents of the applicants;
- **Scientific section:** scientific presentation of the project, maximum 15 pages in length, and which **must follow the template** available on the APOGEE platform and on the page dedicated this Call on the ANRS MIE website;
- **Budget section:** each proposal will include a comprehensive budget detailing the projected costs in HR, operating expenses and equipment for the entire duration of the project, broken down by individual teams as well as aggregated for the whole project (see eligible costs in section 8.1).
- **Bibliography:** must be uploaded separately from the scientific proposal, on the platform.
- **Letter of commitment:** all proposals submitted for funding must include a letter of engagement signed off by each partner as well as an authorized representative of their respective institutions. It is the responsibility of host institutions to verify and certify the appropriateness, completeness and correctness of all information submitted by their researchers as part of their applications for funding. By co-signing applications, institutions commit themselves to administering the funding, if awarded, according to the relevant Terms and Conditions of Funding.

Only the electronic version of documents submitted through Apogée by the Call closing date will be considered for evaluation. Proposals that do not include all required documents will be declared inadmissible and will not be evaluated.

The contact person submitting the application will receive an electronic confirmation when the proposal is submitted.

It is strongly recommended:

- to open an account on the Apogée platform as soon as possible;
- not to wait until the project submission deadline to enter data online and upload files (note: it is imperative to respect the submission deadline);
- to check that the documents submitted are complete and correspond to the expected information and templates;
- to regularly consult the Apogée platform and the ANRS MIE website, which provide up-to-date information on the process;
- to contact, if necessary, the ANRS MIE or DZIF using the email addresses provided page 15.

6.2 Review and Selection Process

All proposals go through a multi-step review process before ANRS MIE and DZIF together make a final funding decision.

Following verification of administrative and scientific eligibility of the applications, proposals will move forward to the external Peer Review stage. At this stage, an independent Peer Review Panel of international scientific experts will review the applications using the criteria described in 6.3.

The Peer Review Panel experts undertake to respect the rules of ethics and scientific integrity established by ANRS MIE and DZIF. The ANRS MIE and DZIF ensure strict compliance with confidentiality rules and the absence of conflicts of interest.

The Peer Review Panel will put forward a ranked list of applications. Based on these recommendations, ANRS MIE and DZIF will make a final decision regarding funding through their respective Executive Management Committees and inform their relevant Boards.

Projects selected for funding may be required to make refinements to the proposed project plan, structure, and/or budget to address reviewer comments and funder requirements before an award and funding agreement are finalized.

6.3 Evaluation Criteria

Review Panel experts will review the full applications according to the following criteria, grouped into four main categories:

1. Scientific excellence and impact

- Alignment with the scope of the call (HIV and/or HBV/HDV cure);
- Degree of conceptual advance beyond the state of the art, and added value relative to existing therapies;
- Strength of the scientific rationale, supported by literature and preliminary/proof-of-concept data;
- Clarity of research objectives and hypotheses;
- Relevance of methodology and feasibility of the proposed approach.
- Where relevant, ability to address the research question through an interdisciplinary approach;
- Quality of the project plan, including the management of scientific risks, alternative strategies, well-defined milestones, a realistic work program, and clear go/no-go decision points.

2. Feasibility of the Project

- Competence, expertise, complementarity and involvement of the project co-leaders: ability to coordinate ambitious international collaborative projects, academic background, international recognition;
- Quality, relevance and complementarity of the scientific consortium in relation to the project's objectives;
- Adequacy of the human and financial resources mobilized (including those requested within the framework of the project), as well as the capacities available within the teams (including regulatory capacities), in relation to the targeted objectives;
- Relevance and effectiveness of project governance (steering, organization, coordination, setting up of advisory committees, involvement of stakeholders if necessary, etc.);
- Where relevant, capacity to involve affected communities and the private sector in co-designing the project from the outset.

3. Project impact

- Contribution of the project to the objectives of the call, to accelerating progress towards HIV and hepatitis cures;
- Impact of the consortium on building international scientific collaboration for the long term;
- Anticipated impact on population health and implementation in public policies, including aspects of co-production of public policies with all stakeholders;

- Economic, social and societal impacts, contribution to the development of solutions to the challenges of HIV cure and Hepatitis Cure;
- Dissemination strategy (*in itinere* and *ex post*) and valorization of results. Ability of the project to meet the challenges of open science, dissemination to the public and transparency in the field of HIV cure and Hepatitis Cure.

4. Innovation and Translation

- Competitiveness of the proposed approach in the scientific field, and use of modern technologies and methods;
- Innovative character of the proposed work and, where relevant, its potential for industrial application and technology transfer;
- Potential to generate proof-of-concept data;
- Realistic pathway to clinical development, including potential for industrial partnership or market uptake.

7. Activities and Deliverables

7.1 Progress report

Research consortia funded under this call will be expected to provide the specific deliverables listed below in order to demonstrate project progress:

- 1) Organization of a kick-off meeting to launch the project.
- 2) Conclude a research collaboration agreement between the project partners, preferably within 6 months of the award being made.
- 3) An interim and final report reporting package comprising:
 - a. one joint scientific progress report covering the overall project, including progress towards the project objectives and deliverables, key findings, and the work plan for the remaining project period;
 - b. two separate financial and technical reports, one per funding organization, each following its own internal reporting rules (see the agreement between ANRS MIE and DZIF for more details).
- 4) Continued post-grant updates on scientific publications and impact.

Instructions for reporting will be provided to successful recipients.

Funds must be used for the purpose and research activities for which they were intended and approved by the DZIF and ANRS MIE. Any significant deviations from the approved project objectives, methodology, milestones and/or deliverables must be approved by both the DZIF and ANRS MIE in writing prior to implementation.

7.2 Dissemination

Recipients of this Call are expected to maximize the impact and utility of their work, including through timeous dissemination of their findings through, for example:

- Social media
- Open access publications
- Depositing of research data into publicly accessible repositories (in compliance with applicable regulations)
- Press releases
- Conferences
- Stakeholder engagement

The ANRS MIE and DZIF acknowledge that recipients may reasonably delay the publication of data and results generated from the projects with the aim of first protecting any potential intellectual property therein.

All publications, press releases and other documents which include results obtained in projects funded through this Call must acknowledge both the DZIF and ANRS MIE in the form indicated in the relevant Funding Agreement or Letter of Acceptance of Grant Conditions. If no statement is stipulated, then the following general statement should be used: *“Research reported in this [publication/press release] was supported by DZIF and ANRS MIE, under the grant numbers XXX and ANRSMIE-R-PR-XXXX”*.

8. Financial Policies

General conditions are set out below. For further details, each institution should contact its respective funding organization.

8.1 Allowable Cost

The following costs are allowable for this Call (all direct line items must be auditable):

- Personnel: Soft-funded posts for individuals working on the project (e.g. post-docs, PhD students up to one per associated team, students, technicians, project managers) will be funded, provided an accurate estimation of time allocation is provided and they are not already funded from other means.
- Equipment: Partial or full support for the cost of equipment may, in some instances, be requested, provided that it is directly required for the project. A budget limitation of 10% of total budget must apply.
- Supplies, consumables and other direct laboratory or research costs.
- Sub-contracts: These may be to any local or international private organization or individual engaged as consultant providing a service or capability that is not

available among the project partners but is essential for the completion of project deliverables. These should not exceed 20% of the total project budget.

- Travel and accommodation that is directly related to the execution of the project, following the rules of the institution.
- Institutional overhead: Institutions funded by ANRS MIE may apply an indirect cost rate of up to 8%. any overhead are not eligible Institutions funded by DZIF.

Non-allowable costs include the following:

- Salaries of permanent or fixed term staff, e.g. tenured staff, professors etc..
- Purchase or construction of a building.
- Rental costs for space that is owned by the institutions participating in the project.

If research equipment is purchased through this Call, it becomes the property of the host institution. Under no circumstances may equipment become the property of the individual researcher to whom the funding was allocated. The equipment may not be removed from the host institution and/or transferred to another institution without the express written approval of the host institution and concurrence by the DZIF and ANRS MIE. The institution must take responsibility for any necessary maintenance and insurance of the equipment.

8.2 Terms of Disbursement

Specific disbursement rules may apply depending on the funder.

In general terms, successful applicants, depending on the respective funder, must enter into a Funding Agreement or sign a Letter of Acceptance of Grant Conditions with the DZIF or ANRS MIE before any funds are disbursed where the conditions of funding will be carefully detailed.

The frequency of funding disbursements will be as stipulated in the approved budget. Funding disbursements are subject to the submission of ethics approvals and satisfactory progress and financial reports. Funding disbursements may be delayed or altered, at the discretion of the DZIF and ANRS MIE, if insufficient spending has occurred on previous instalments.

8.3 Fund Management

The host institutions are required to ensure that the procurement of any goods, equipment and/or services for the purposes of the project are in strict accordance with the provisions of the institutions' procurement and travel policies. Funds may be spent solely according to the approved project budget and proposal.

Additional specific fund management rules may apply depending on the funder.

At the end of the contractual term and/or upon completion of the project deliverables, any surplus project funds are to be re-paid to the DZIF or ANRS MIE unless an alternative use for the funds by the institution has been agreed in writing by the DZIF and/or ANRS MIE.

The DZIF and ANRS MIE are entitled, at any reasonable time during or after the project, to appoint an independent team of auditors to inspect and take copies of the project books of account, records and supporting documents of the institution to the extent necessary to verify any statement on reasonable notice and during office hours. The institution must for this purpose provide the auditors with reasonable access to the books of account, technical reports and all records relating to the management of the project together with any other information required by the auditors for this purpose.

The Institution is also required to inform the DZIF and ANRS MIE in writing of any and all other funding for the project from third parties, which is used in the furtherance of the project. Additional funding should not be duplicative (i.e. double dipping) of funds received from the DZIF and ANRS MIE.

9. General Policies And Terms

9.1 Submission Materials and Privacy Notice

The proposals submitted in response to this Call will be subject to external review by international subject-matter experts, in addition to analysis by staff from both DZIF and ANRS MIE. Please be advised that a copy of the external review for each submitted proposal may be disclosed to ANRS MIE and DZIF Executive Management Committees and Boards.

ANRS MIE and DZIF will exercise all reasonable efforts to respect the confidentiality of information that is received in Submission Materials. ANRS MIE and DZIF reserve the right to publicly disclose the titles, public summary and names and institutions of co-investigators, as well as the amount of funding granted, for each successful application.

9.2 Open Science/Sharing and Access Policy

In agreement with the promotion and implementation of open science, beneficiaries of this Call are committed to guaranteeing immediate open access to peer-reviewed scientific publications, and to adopt a FAIR (Easy to Find, Accessible, Interoperable,

Reusable) approach to manage research data in line with the principle of "as open as possible, as closed as necessary".

In particular, recipients agree:

- To make publications arising from the project immediately openly discoverable and accessible online under a Creative Commons Attribution (CC BY) or equivalent license, in one of the following three ways:
 - publication in a natively open access journal;
 - publication in a subscription journal that is part of a so-called transforming agreement or transforming journal;
 - publication in a subscription journal. The editor's version or the manuscript accepted for publication will be deposited in the French open archive HAL by the authors under a CC- BY license, in compliance with the rights retention strategy, as specified in the funding decision or contract.
- To deposit in the French national HAL open archive, the full text of these scientific publications at the latest at the time of publication, (version accepted for publication or publisher's version) and to mention the grant from which they originate.
- To employ best efforts and endeavour in good faith to deposit project data outputs into a relevant open access repository within 12 months of project completion.
- To employ best efforts and endeavour in good faith to openly and publicly disseminate results and conclusions of the project, whether positive, neutral, or negative, within 12 months of project completion.
- To provide ANRS MIE and DZIF with a Data Management Plan (DMP) for the whole project. A first version of the DMP must be provided within 6 months of the start of the project. This plan should be updated as necessary, at least at the end of the project and at mid-term. The plan can be entered and updated on the [OPIDoR DMP portal](#), using the so-called structured, machine-readable model.

Recipients are encouraged to deposit publication's initial versions, or "pre-prints", in open platforms or open archives, and to give preference to perennial or unique identifiers (DOI, HAL Id or ORCID, for example).

Publication costs or "Article Processing Charges" (APC) are eligible for partial ANRS MIE funding and partial DZIF funding, with the exception of those hybrid journals (subscription journals with no current agreement).

9.3 Intellectual Property

Successful applicants may retain ownership of intellectual property rights in supported innovations, including innovations that arise from the funded projects. ANRS MIE and DZIF aim, however, to ensure that any such intellectual property rights are utilized and managed in a manner that is consistent with achieving the goal of this Call.

In particular, successful applicants agree to employ best efforts and endeavour in good faith to provide widespread, affordable and equitable access to the supported innovations to achieve the greatest possible impact for those most in need.

ANRS MIE and DZIF recognize the value of intellectual property and commercialization, and the benefits of first and continuing use of data, but not prolonged or exclusive use. In some cases, intellectual property protection, laws or regulations may delay or preclude access to data. In cases where an adequate justification has been provided, ANRS MIE may grant a partial or complete waiver of the data access requirement.

9.4 Regulatory and Ethical Compliance

The ANRS MIE and DZIF are committed to ensure that research involving human biological samples, research with animals, and research subject to additional regulatory requirements is conducted in accordance with the highest internationally recognized ethical standards.

Recipients of this Call are required to obtain approval for any research involving human or animal subjects or samples therefrom from the appropriate institutional review board or ethics committee and provide the ANRS and DZIF with a copy of such approval prior to embarkation on the research. This requirement extends to all sites participating in the research.

Any such research must, in addition to ethical approval compliance, be conducted in accordance with the generally accepted principles of “Good Clinical Practices”, which shall include but not be limited to, requiring prior informed consent from the human subjects and shall be conducted in accordance with all applicable national and international regulations and guidelines pertaining to research involving human subjects, management of data confidentiality, research involving animals, use or release of genetically modified organisms, research use of recombinant DNA, and/or use of any organism, substance or material considered to be a biohazard, including adherence to all applicable standards for transport of specimens, both locally and internationally, as appropriate.

9.5 Other Commitments

Environmental sustainability

ANRS MIE and DZIF require that applicants commit to ensuring that their research project will not have significant adverse environmental effects including, but not limited to, long-term and cumulative effects.

Investigators are invited to include in their projects an assessment of its environmental impact, in particular an estimate of the carbon footprint of travel and other activities required to carry out the project, as well as the justification for these activities and/or the means proposed to limit their impact on the environment.

Useful resources (principles and tools) for this assessment can be found here: <https://labos1point5.org>; www.basecarbone.fr.

Gender equality

ANRS MIE and DZIF are committed to furthering principles of gender equality in the research projects funded under this Call.

As such, several actions have been implemented by ANRS MIE to avoid potential gender bias in project evaluation, to contribute to the evolution of scientific culture towards a systematic consideration of the sex and/or gender dimension in research work and evaluation, and to enhance the place and role of women in science.

Human rights

ANRS MIE and DZIF are committed to furthering a Human Rights Based Approach. This particularly includes the promotion of principles of participation, inclusion, equity, transparency, and accountability in an applicant's project.

10. Contacts

Each project funded through this Call is managed by specific joint call secretariat from DZIF and ANRS MIE Project Managers who will be the primary contact for all queries and communications thereon.

Any general queries in relation to these Funding Terms and Conditions may be addressed to:

aap@anrs.fr and flexfunds@dzif.de.

For technical assistance with registration or online application through Apogée, please contact:

apogee@anrs.fr

Appendix:

DZIF Member Institutions, Associated Partner Institutions and Associated Partners

(September 2026)

DZIF Member Institutions	
<i>All PIs at DZIF member institutions can apply for DZIF flexible funds.</i>	
1	Hannover Medical School
2	University of Veterinary Medicine Hannover
3	TWINCORE - Centre for Experimental and Clinical Infection Research
4	Helmholtz Centre for Infection Research
5	Leibniz Institute DSMZ–German Collection of Microorganisms and Cell Cultures
6	Technische Universität Braunschweig
7	Robert Koch Institute
8	Bernhard Nocht Institute for Tropical Medicine
9	University Medical Center Hamburg-Eppendorf
10	University of Hamburg
11	Universität zu Lübeck
12	Leibniz Institute of Virology
13	Research Center Borstel, Leibniz Lung Center
14	Friedrich-Loeffler-Institut
15	University of Bonn
16	University Hospital Bonn
17	University of Cologne
18	University Hospital Cologne
19	Federal Institute for Drugs and Medical Devices
20	University of Tübingen
21	University Hospital Tübingen
22	Max Planck Institute for Biology Tübingen (until end of 2026)
23	Technical University of Munich
24	TUM University Hospital
25	Ludwig-Maximilians-Universität München
26	LMU University Hospital Munich
27	Helmholtz Munich
28	Bundeswehr Institute of Microbiology
29	Heidelberg University
30	Heidelberg University Hospital
31	German Cancer Research Center
32	Justus Liebig University Giessen
33	Marburg University
34	Paul-Ehrlich-Institut
35	Mittelhessen University of Applied Sciences (until end of 2026)

Associated Partner Institutions	
<i>All PIs at associated partner institutions can apply for DZIF flexible funds.</i>	
Fraunhofer Institute for Translational Medicine and Pharmacology ITMP	
Leibniz Institute for Natural Product Research and Infection Biology—Hans Knöll Institute (Leibniz-HKI)	
European Molecular Biology Laboratory (EMBL), Heidelberg	

Associated Partners	
<i>Associated partners can apply for DZIF flexible funds. Associated partners are PIs with DZIF funding at German universities and research institutions which are not DZIF members. If the DZIF funding expires, the PI also loses the status „associated partner“.</i>	
Institution	Associated Partners
Medical Center—University of Freiburg	Robert Thimme, Maïke Hofmann, Tobias Böttler, Bodo Grimbacher, Tobias Feuchtinger, Theresa Käuferle, Siegbert Rieg
Charité - Universitätsmedizin Berlin	Christian Drosten, Marcel Müller, Victor Corman, Felix Drexler, Sandra Junglen, Florian Kurth, Birgit Sawitzki, Christine Geffers, Luisa Denkel
German Liver Foundation	associated with Hannover Medical School
Johann Wolfgang Goethe-Universität Frankfurt	Jörg Janne Vehreschild, Maria Vehreschild, Sandra Ciesek
RWTH Aachen University	Thomas Clavel
University of Bayreuth	Andreas Römpf
Greifswald University Medicine	Karsten Becker
Ruhr University Bochum	Eike Steinmann
Jena University Hospital	Mathias Pletz
Max Delbrück Center for Molecular Medicine	Markus Landthaler, Emanuel Wyler
Leipzig University	Florian van Bömmel
Deutsches Primatenzentrum – Leibniz Institut für Primatenforschung	Stefan Pöhlmann